SCHEMBL650807

SCHEMBL650807

O=C(O)CCC(=O)Nc1ncc(/C=C2\S/C(=N\c3ccc(O)cc3)NC2=O)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.48
GSK3B P49841 1/20 0.48
MEN1 O00255 10/20 0.46
KMT2A Q03164 10/20 0.46
POLB P06746 8/20 0.46
MAPT P10636 7/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPK1 P28482 1/20 0.46
LMNA P02545 2/20 0.44
PKM P14618 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KDM4E B2RXH2 1/20 0.44
GAA P10253 1/20 0.44
NPC1 O15118 4/20 0.43
PTPN7 P35236 2/20 0.42
DUSP3 P51452 2/20 0.42
PTPN12 Q05209 2/20 0.42
PTPN22 Q9Y2R2 2/20 0.42
PTPN5 P54829 1/20 0.42
PTPN11 Q06124 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649726 1.00 SYK (0.48) SYKGSK3BMEN1KMT2APOLB
SCHEMBL653261 0.93 NPC1 (0.50) GSK3BMEN1KMT2APOLBMAPT
SCHEMBL653260 0.93 NPC1 (0.50) GSK3BMEN1KMT2APOLBMAPT
SCHEMBL649044 0.92 MEN1 (0.46) SYKMEN1KMT2APOLBMAPT
SCHEMBL649045 0.92 MEN1 (0.46) SYKMEN1KMT2APOLBMAPT
SCHEMBL651137 0.91 POLB (0.45) MEN1KMT2APOLBMAPTLMNA
SCHEMBL651131 0.91 POLB (0.45) MEN1KMT2APOLBMAPTLMNA
SCHEMBL651435 0.90 POLB (0.54) MEN1KMT2APOLBMAPTLMNA
SCHEMBL651434 0.90 POLB (0.54) MEN1KMT2APOLBMAPTLMNA
SCHEMBL13091415 0.90 PTPN11 (0.42) SYKGSK3BMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 SYK 3787/4885GSK3B 305/4885MEN1 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.